RET-IN-19 (compound 59) 是一种有效的RET抑制剂，对RET-wt和RET V804M的IC50值分别为 6.8 和 13.51 nM。RET-IN-19 具有抗癌活性。RET-IN-19 可用于非小细胞肺癌 (NSCLC) 研究。

RET-IN-19 (compound 59) is a potent RET inhibitor, with IC 50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research [1].

RET-IN-19 (compound 59) shows growth inhibition of LC-2/ad cells which RET-CCDC6 driven, with a GI 50 of 0.1067 ± 0.004 μM [1]. RET-IN-19 (3 μM) shows inhibition of LC-2/ad cells migration [1]. RET-IN-19 inhibits EGFR, Aurora A, Aurora B, Nek2, CSF-1R, MAP4K4, NIK, and RET, with IC 50 values of 56.78 ± 4.94, 0.242 ± 0.036, 0.536 ± 45.12, >200, 1.65 ± 0.235, 3.428 ± 0.150, >10, and 0.0068 ± 0.0003, respectively [1].

2484919-71-1

C28H28N6O4S

544.62

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years